Government & Community Affairs at NYU Langone Health | NYU Langone Health
NYU Langone Health works with government and community organizations to create healthier communities in the New York metropolitan area.
Grace Y. Ko | NYU Langone Health
Grace Y. Ko, NYU Langone’s executive vice president for development and alumni affairs, is responsible for raising philanthropic support.
Graves’ Disease in Children | NYU Langone Health
Experts at Hassenfeld Children’s Hospital at NYU Langone treat children and adolescents with Graves’ disease, an autoimmune condition.
Group Psychotherapy | NYU Langone Health
Specialists at NYU Langone Psychiatry Associates offer group psychotherapy to help facilitate personal growth and healing.
Growth Plate Injuries in Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital at NYU Langone diagnose and treat growth plate injuries in children and adolescents.
GS-US-457-6411: A Phase 2 Double-Blinded Randomized Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants with Moderately to Severely Active Ulcerative Colitis
The goal of this study is to learn if investigational drug tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.
Guided Meditation & Relaxation | NYU Langone Health
NYU Langone’s integrative health experts offer guided meditation and relaxation to help manage stress, anxiety, and pain, and promote wellness.
Guidelines for Building Disability Inclusion and Accessibility into Healthcare Emergency Management
This is a research study on improving the accessibility of healthcare emergency management practice among people with disabilities (visible and invisible).
GUT KIDNEY AXIS IN ENTERIC HYPEROXALURIA - A clinical prospective study of the effects of the microbiome on urinary oxalate in participants with enteric hyperoxaluria fed a moderate oxalate diet
40 subjects with a confirmed diagnosis of IBD or >6 months post-RYGB with a diagnosed USD event or kidney stone on imaging within the past three years and 40 healthy subjects will be administered a high oxalate diet on Days 0-3 and Days 21-24 with a washout period on Days 4-7 and will be administered 250mg sodium oxalate on Days 8-20, via prepared spinach, from Weil Cornell Medicine’s Clinical and Translational Science Center. Subjects will partake in four stool collections, four 24-h urine collections, two blood collections, and four sets of colonic permeability testing.Subjects are placed on prepared-controlled diets obtained from the metabolic kitchen at Weill Cornell Medicine’s Clinical and Translation Science Center with moderately high oxalate (MOx) during Days 0-3 and Days 21-24. Diets will contain 16% protein, 30% fat, and 54% carbohydrate, and are controlled in the amounts of calcium (400mg), oxalate (250mg), ascorbic acid (50mg), fiber (30 grams) and other nutrients. The MOx diet will be compared against healthy controls with no chronic diseases, not on any chronic medications, no history of GI pathology, or urinary stone disease (USD).
Gut microbiome alterations as a mechanism of immune dysregulation in new-onset refractory status epilepticus (NORSE)
We will perform a prospective, observational cohort study, with biospecimen collection, of NORSE subjects and subjects with status epilepticus of known cause (e.g. epilepsy, stroke, traumatic brain injury) serving as disease controls. Biospecimens to be collected include serum, CSF, and feces, which will all be analyzed in conjunction with relevant clinical outcome measures collected via prospective chart reviews of these subjects' hospital stays. These analyses will allow us to test our hypothesis that in subjects with status epilepticus, gut dysbiosis leads to IL-1b upregulation, which enhances neuronal hyperexcitability and contributes to refractory status epilepticus.